NEURAL TUBE DEFECTS
The neural plate appears on the 17th day of gestation as a thickening of the embryonic ectoderm over the notochord. This neuroectoderm gives rise to the central nervous system. On day 18, the neural plate invaginates along the midline, forming the neural groove with the neural folds on either side. By the end of the third gestational week, the neural folds fuse forming the neural tube. The cranial end of the neural tube closes by 24 days and the caudal by 25-26 days. Then, the neural tube is covered dorsally by mesenchyme that forms the vertebral ardhes and skull. Closure of the vertebral arches is completed at 11 weeks of gestation. Defective closure of the neural tube results in neural tube defects (NTDs) which are classified as anterior (anencephaly, encephalocele) and posterior (spina bifida).![]() |
![]() |
![]() |
| Exencephaly | Anencephaly | Anencephaly |
![]() |
![]() |
| Myelomeningocele | Massive NTD |
Spina bifida is a set of malformations of the spinal cord caused by failure of closure of the neural tube and lack of fusion of the vertebral arches, soft tissues, and skin that cover the back. The lesion is usually in the lumbosacral area but sometimes it can be more extensive and may involve the entire spinal cord. In its mildest form, spina bifida occulta, the vertebral arches are absent, but there is a hairy patch of skin over the defect. The spinal cord may be normal or the filum terminale may be tethered to subcutaneous tissue. Meningocele is a bulge in the lumbosacral area consisting of a meningeal sac protruding through the bone defect. In meningomyelocele, the sac contains malformed spinal cord tissue. In severe cases, there is no sac at all, and neural tissue from the open neural plate lies on the dorsal surface of the fetus. Anencephaly is often accompanied by spina bifida.
![]() |
| Encephalocele |
NTDs are the most common congenital abnormalities of the CNS and, overall, the second most common type of congenital abnormality after congenital heart disease. They are a significant cause of fetal loss. Live-born babies with myelomeningoceles may have paralysis of the legs and loss of bladder and bowel function. Open defects allow entry of bacteria into the CNS. The same thing happens if the skin covering the meningomyelocele becomes necrotic and infected. Some meningomyeloceles are a component of a more complex malformation, the Chiari II malformation, which includes hydrocephalus and abnormalities of the posterior fossa contents (see Chiari malformations further on).
Neural tube defects can be detected in utero by determination of alpha-fetoprotein (AFP) and acetylcholinesterase in the amniotic fluid and maternal blood. Alpha- fetoprotein, a circulating fetal protein produced by the liver, peaks at 12-14 weeks of gestation and subsequently declines. AFP leaks from the fetus into the amniotic fluid through exposed capillaries of the NTD. This results in persistently high levels of AFP in the amniotic fluid and in the maternal blood. Elevated AFP is also seen in other lesions where fetal capillaries are exposed to the amniotic fluid such as omphalocele and sacrococcygeal teratoma. Acetylcholinesterase leaks directly from exposed neural tissue into the amniotic fluid.
NTDs develop during the third to fourth week of gestation and are due to a combination of genetic and environmental causes (multifactorial). The genetic causes are unknown. Environmental causes include diabetes mellitus and the antiepileptic drug valproate. Administration of 0.4 mg of folic acid in the period from 4 weeks before to 8 weeks after conception significantly reduces the occurrence of NTDs. The mechanism of action of folic acid in preventing NTDs is not known. Women who have children with NTDs are not overtly folate deficient. However, the rapidly dividing cells of the neural tube probably require a large amount of folate for DNA synthesis. Supply of folate may be inadequate because of gene defects that result in subtle abnormalities of folate metabolism. Two mutations of the folate dependent enzyme 5,10-Methylenetetrahydrofolate reductrase (MTHFR), MTHFR C677T and MTHFR A1298C, are associated with an increased risk for NTDs.






